Torley Helen, President and CEO of Halozyme Therapeutics (HALO), filed 25 transactions with the SEC between June 2 and August 19, 2026. All filings were for the same company, and the pattern is uniformly one-sided: 19 open-market sales (code "S") and 6 option exercises (code "M"), with zero purchases. The total value of sales reached $45,060,875.76, while the option exercises, which are compensatory rather than discretionary, totaled $1,489,600.
The selling activity was concentrated in three clusters. On June 2 and 3, Helen sold shares worth $226,933, $1,100,812.40, $101,512.50, and $26,547.20, alongside two option exercises of $120,700 and $241,400. A second cluster occurred on July 8, with sales of $82,993.55 and $70,397.09, paired with a $23,210.61 option exercise. The largest cluster came in August: on August 17, 18, and 19, Helen executed nine sales totaling $4,760,634.85, with values per transaction ranging from $50,228.50 to $1,029,350.40, plus three option exercises of $368,200 each.
The data shows a clear selling bias over the three-month window, with no open-market purchases recorded. The August transactions alone accounted for roughly 10.6% of the total sales value, indicating an acceleration in disposition activity. The option exercises, all coded "M," represent the acquisition of shares through existing compensation plans, which were then sold in the open market. No transactions were coded as gifts ("G"), conversions ("C"), or sales back to the issuer ("D"). The filings provide no indication of the reasons behind the sales, and the pattern is consistent with routine portfolio management by an executive officer.
AI-assisted summary